Biopolym. Cell. 2008; 24(3):212-217.
Структура та функції біополімерів
Ефекти тейхоєвої кислоти Staphylococcus aureus
при пухлинному рості
1Сківка Л. М., 1Рудик М. П., 1Позур В. В., 1Сенчило Н. В., 1Позур В. К., 1Фурзікова Т. М.
- Київський національний університет імені Тараса Шевченка
вул. Володимирська 64, Київ, Україна, 01601
Abstract
Досліджували вплив тейхоєвої кислоти S. aureus Wood 46 на ріст і метастазування карциноми легені Л’юїс у мишей. Введення тейхоєвої кислоти у дозі 2 мкг/г одночасно з трансплантацією пухлинних клітин гальмувало ріст первинної пухлини і запобігало утворенню легеневих метастазів у дослідних тварин.
Keywords: тейхоєва кислота, карцинома легені Л’юїс
Повний текст: (PDF, українською)
References
[1]
Zaridze DG. Epidemiology, mechanisms of cancerogenesis and prevention of neoplasms. Arkh Patol. 2002;64(2):53-61.
[2]
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539-45.
[3]
Bobrovnik SA. Infection, autoimmune diseases, atherosclerosis, infarct, stroke, cancerogenesis: what is in common. Ukr Biokhim Zh. 2002;74(4):135-40.
[5]
Keller R, Keist R, Gustafson JE. Antitumor activity of bacteria and bacterial products: enhancement of the tumor-protective effect of bacteria by lipoteichoic acid. Cancer Lett. 1994;82(1):99-104.
[6]
Konturek PC, Konturek SJ, Pierzchalski P, Bielanski W, Duda A, Marlicz K, Starzynska T, Hahn EG. Cancerogenesis in Helicobacter pylori infected stomach--role of growth factors, apoptosis and cyclooxygenases. Med Sci Monit. 2001;7(5):1092-107.
[8]
Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 2000;103(3):481-90.
[9]
Maeda H, Akaike T, Wu J, Noguchi Y, Sakata Y. Bradykinin and nitric oxide in infectious disease and cancer. Immunopharmacology. 1996;33(1-3):222-30.
[10]
Terman DS. Protein A and staphylococcal products in neoplastic disease. Crit Rev Oncol Hematol. 1985;4(2):103-24.
[11]
Quan WD Jr, Palackdharry CS. Common cancers--immunotherapy and multidisciplinary therapy: Parts III and IV. Dis Mon. 1997;43(11):745-808.
[12]
Shimizu M, Matsuzawa A, Takeda Y. A novel method for modification of tumor cells with bacterial superantigen with a heterobifunctional cross-linking agent in immunotherapy of cancer. Mol Biotechnol. 2003;25(1):89-94.
[13]
Wang Q, Yu H, Zhang L, Ju D, Pan J, Xia D, He L, Wang J, Cao X. Vaccination with IL-18 gene-modified, superantigen-coated tumor cells elicits potent antitumor immune response. J Cancer Res Clin Oncol. 2001;127(12):718-26.
[14]
Lycke N. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM. Cell Microbiol. 2004;6(1):23-32.
[15]
Hara I, Sato N, Miyake H, Muramaki M, Hikosaka S, Kamidono S. Introduction of 65 kDa antigen of Mycobacterium tuberculosis to cancer cells enhances anti-tumor effect of BCG therapy. Microbiol Immunol. 2004;48(4):289-95.
[16]
Mastrangelo MJ, Maguire HC Jr, Sato T, Nathan FE, Berd D. Active specific immunization in the treatment of patients with melanoma. Semin Oncol. 1996;23(6):773-81.
[17]
Sekine K, Ohta J, Onishi M, Tatsuki T, Shimokawa Y, Toida T, Kawashima T, Hashimoto Y. Analysis of antitumor properties of effector cells stimulated with a cell wall preparation (WPG) of Bifidobacterium infantis. Biol Pharm Bull. 1995;18(1):148-53.
[18]
Wang JE, Dahle MK, McDonald M, Foster SJ, Aasen AO, Thiemermann C. Peptidoglycan and lipoteichoic acid in gram-positive bacterial sepsis: receptors, signal transduction, biological effects, and synergism. Shock. 2003;20(5):402-14.
[19]
Sriskandan S, Cohen J. Gram-positive sepsis. Mechanisms and differences from gram-negative sepsis. Infect Dis Clin North Am. 1999;13(2):397-412.
[20]
Calvinho LF, Almeida RA, Oliver SP. Influence of bacterial factors on proliferation of bovine mammary epithelial cells. Rev Argent Microbiol. 2001;33(1):28-35.
[21]
Heumann D, Glauser MP, Calandra T. Molecular basis of host-pathogen interaction in septic shock. Curr Opin Microbiol. 1998;1(1):49-55.
[22]
Bruserud O, Wendelbo O, Paulsen K. Lipoteichoic acid derived from Enterococcus faecalis modulates the functional characteristics of both normal peripheral blood leukocytes and native human acute myelogenous leukemia blasts. Eur J Haematol. 2004;73(5):340-50.
[23]
Okamoto M, Ohe G, Oshikawa T, Furuichi S, Nishikawa H, Tano T, Ahmed SU, Yoshida H, Moriya Y, Saito M, Sato M. Enhancement of anti-cancer immunity by a lipoteichoic-acid-related molecule isolated from a penicillin-killed group A Streptococcus. Cancer Immunol Immunother. 2001;50(8):408-16.
[24]
Okamoto M, Ohe G, Furuichi S, Nishikawa H, Oshikawa T, Tano T, Ahmed SU, Yoshida H, Moriya Y, Matsubara S, Ryoma Y, Saito M, Sato M. Enhancement of anti-tumor immunity by lipoteichoic acid-related molecule isolated from OK-432, a streptococcal agent, in athymic nude mice bearing human salivary adenocarcinoma: role of natural killer cells. Anticancer Res. 2002;22(6A):3229-39.
[25]
Gao JJ, Xue Q, Zuvanich EG, Haghi KR, Morrison DC. Commercial preparations of lipoteichoic acid contain endotoxin that contributes to activation of mouse macrophages in vitro. Infect Immun. 2001;69(2):751-7.
[26]
Levels JH, Abraham PR, van Barreveld EP, Meijers JC, van Deventer SJ. Distribution and kinetics of lipoprotein-bound lipoteichoic acid. Infect Immun. 2003;71(6):3280-4.
[27]
Kutsenok VV, Skivka LM, Gorobetc OB, Lozinski MO, Borisevich A. H, Choline VV, Gamaleja NF 5-Aminolevulinic acid as a photosensitizer for photodynamic tumor therapy (preclinical studies). Onkologiia. 2004. 5(3):225–230.
[28]
Rashba Ye. YA., Matsyuk V. M., Musiyenko V. I. A-17 homogenizer. Disintegration of microorganisms. Pushchino-na-Oke, 1972:159-162.
[29]
Archibald AR Research Methods carbohydrates. M: Vyssh. shkola,, 1975. 350.
[30]
Shashkov AS, Streshinskaya GM, Kozlova YuI, Potekhina NV, Taran VV, Evtushenko LI, Naumova IB. Structure of cell wall teichoic acid of Nocardiopsis alborubida. Biokhimiia. 1997; 62(10):1327–31.
[31]
Taussky HB, Shorr E., Kurzmann G. A microcolorimetric method for the determination of inorganic phosphorus. J Biol Chem. 1953;202(2):675-85.
[32]
Glaser L., Burger M. The synthesis of teichoic acid. 3 Glucosylation of poly glycerolphosphate. J Biol Chem. 1964;239:3187-91.
[33]
Streshinskaya GM, Kozlova YuI, Evtushenko LI, Taran VV, Shashkov AS, Naumova IB. Teichoic acid of Nocardiopsis ssp. VKM Ac-1457 cell walls. Biokhimiia. 1996; 61(2):378–82.
[34]
Skivka LM, Putnikov AV, Pozur VV, Pozur VK. Effect intaktyvovanoho S. aureus growth Lewis carcinoma in mice. Visn. ONU., 2004. 10, 3:155-162.
[35]
Kengatharan KM, De Kimpe SJ, Thiemermann C. Role of nitric oxide in the circulatory failure and organ injury in a rodent model of gram-positive shock. Br J Pharmacol. 1996;119(7):1411-21.
[36]
Nau R, Eiffert H. Minimizing the release of proinflammatory and toxic bacterial products within the host: a promising approach to improve outcome in life-threatening infections. FEMS Immunol Med Microbiol. 2005;44(1):1-16.
[37]
Janssens S, Beyaert R. Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev. 2003;16(4):637-46.
[38]
Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol. 2002;168(2):554-61.
[39]
Netea MG, van der Graaf C, Van der Meer JW, Kullberg BJ. Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. J Leukoc Biol. 2004;75(5):749-55.
[40]
Moreno C., Sanchez-Ibarrola A. Toll type receptors: molecular bases of the relationship between innate and adaptation responses of the immune system. Rev Med Univ Navarra. 2003;47(3):29-33.
[41]
Palaniyar N, Nadesalingam J, Reid KB. Pulmonary innate immune proteins and receptors that interact with gram-positive bacterial ligands. Immunobiology. 2002;205(4-5):575-94.
[42]
Middelveld RJ, Alving K. Synergistic septicemic action of the gram-positive bacterial cell wall components peptidoglycan and lipoteichoic acid in the pig in vivo. Shock. 2000;13(4):297-306.
